<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613402</url>
  </required_header>
  <id_info>
    <org_study_id>18-025</org_study_id>
    <nct_id>NCT03613402</nct_id>
  </id_info>
  <brief_title>BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes</brief_title>
  <official_title>BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 - Evaluate the real-world implementation of extended prophylaxis with betrixaban in
      the acutely ill hospitalized medical population Part 2 - Describe patterns of Venous
      thromboembolism (VTE) prophylaxis in acutely ill medical patients who qualify for extended
      VTE prophylaxis
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to slow enrollment.
  </why_stopped>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombotic Events at 45 days: VTE, MI, Stroke, Transient ischemic attack (TIA)</measure>
    <time_frame>45 days</time_frame>
    <description>Thrombotic Events at 45 days: VTE, MI, Stroke, TIA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding rates at 45 days</measure>
    <time_frame>45 days</time_frame>
    <description>Bleeding rates at 45 days</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Thromboses</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients at risk of VTE who are prescribed betrixaban to prevent VTE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acutely ill medical patients, hospitalized, prescribed therapy for VTE prophylaxis and who
        would qualify for extended prophylaxis (whether or not they receive prophylaxis).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Part 1 -

          1. Hospitalized acutely ill medical patient

          2. Patient prescribed betrixaban

          3. Signed informed consent

        Part 2 -

          1. Hospitalized acutely ill medical patient

          2. Patient prescribed betrixaban OR must satisfy criteria a and b:

               1. Moderately or severely restricted immobility: patient restricted to bed for at
                  least 24 hours (severe) or restricted to bed for at least 12 hours (moderate)
                  during their hospitalization

               2. At least One additional risk factor:

        Age &gt; 70 years D-dimer &gt; 2x institutional Upper Limit of Normal (ULN) Obesity: Body mass
        index (BMI) &gt; 30 kg/m2) History of pulmonary embolism (PE) or deep venous thrombosis (DVT)
        Active cancer (diagnosed, treated, or progressing in the past 6 months) History of
        thrombophilia Recent trauma or surgery (within 30 days prior to admission) Ongoing hormonal
        treatment ICU stay 3. Signed informed consent

        Exclusion Criteria:

          -  Part 1 - 1. High bleeding risk - any of the following:

               1. Patient on dialysis

               2. Low platelet count (&lt;50 per 109/L)

               3. Known bleeding disorder (congenital or acquired)

               4. Liver disease prohibitive to anticoagulation

               5. Bleeding within last 30 days

               6. Use of Dual Anti-Platelet Therapy (DAPT)

        Part 2

          1. Patients who are on another oral anticoagulant (OAC) for any reason at the time of
             hospitalization and will remain on it

          2. Condition requiring use of OAC at admission, other than VTE prophylaxis (eg, acute VTE
             at admission)

          3. High bleeding risk any of the following:

               1. Patient on dialysis

               2. Low platelet count (&lt;50 per 109/L)

               3. Known bleeding disorder (congenital or acquired)

               4. Liver disease prohibitive to anticoagulation

               5. Bleeding within last 30 days

               6. Use of Dual Anti-Platelet Therapy (DAPT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

